Document is current
Any future updates will be listed below
-
Authors
Thiant, Stéphanie https://orcid.org/0009-0002-7950-9354
Dufresne, Simon
Ahmad, Imran https://orcid.org/0000-0003-1899-0164
Cohen, Sandra
Delisle, Jean-Sébastien
Fernandez-Vargas, Omar Eduardo https://orcid.org/0000-0001-8354-3374
Kiss, Thomas
Lachance, Silvy https://orcid.org/0000-0001-7882-9335
Roy, Denis Claude
Veilleux, Olivier
Bernard, Léa
Gisela Rodriguez, Daiana
Sauvageau, Guy https://orcid.org/0000-0002-4333-7266
Roy, Jean https://orcid.org/0000-0002-7716-6864
-
Funding
Funding for this research was provided by:
Maryse and William Brock Chair for Clinical Research into Stem Cell Transplantation
- License Information
-
More Information
Article History
Received: 21 January 2026
Revised: 31 March 2026
Accepted: 28 April 2026
First Online: 9 June 2026
Competing interests
: IA: consultancy for AbbVie, Jazz Pharmaceuticals, Medexus, Sanofi and Vertex Pharmaceuticals. JR: consultancy for Amgen, Sanofi, Janssen, royalties from sales of UM171. SC: consultancy for the clinical program of ExCellThera, royalties from sales of UM171. JSD: royalties from sales of UM171. SL: royalties from sales of UM171. GS: royalties from sales of UM171. Other authors declare no conflict of interest.
